VASPIT ® is a Fluorcortinbutylester based drug
THERAPEUTIC GROUP: Non-associated corticosteroids
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications VASPIT ® Fluorcortinbutilestere
VASPIT ® is a medicinal specialty indicated for the treatment of skin diseases such as dermatitis, dermatitis, eczema, erythema, first-degree burns and insect bites.
Mechanism of action VASPIT ® Fluorcortinbutylester
The Fluorcortinbutyl ester, active ingredient of VASPIT ®, is a synthetic corticosteroid similar to Hydrocortisone activity but characterized by more advantageous pharmacokinetic properties, which considerably limit the systemic absorption of the active principle, improving instead its penetration between the various skin layers.
Once the cellular environment is reached, the Fluorcortinbutylester induces the expression of the lipocortin A protein, inhibitor of the enzyme phospholipase A2, initiator of the cascade of molecular events that leads to the formation of inflammatory mediators such as prostaglandins, prostacyclines and thromboxanes.
This control results in an anti-inflammatory, anti-edema, vasoconstrictor and antipruritic activity, thus ensuring excellent control of the complained symptomatology.
The modest portion of absorbed drug is effectively disposed of through the urine following an effective hepatic metabolism.
Studies carried out and clinical efficacy
A NATURAL APPROACH TO DERMATITIS
Holist Nurs Pract. 2003 Jan-Feb; 17 (1): 56-62.
Interesting work that demonstrates the usefulness of chamomile-based extracts in reducing the classic signs of local inflammation and irritation present in the course of atopic dermatitis eczema, thus effectively reducing all the potential side effects associated with classic topical corticosteroid therapy such as Fluorocortinbutilestere.
contact dermatitis TO FLUOROCORTINBUTILY
Contact Dermatitis. 1994 Oct; 31 (4): 271-2.
Clinical case that reveals the appearance of allergic contact dermatitis in a patient undergoing topical treatment with Fluorocortinbutylester, thus reiterating all the potential side effects of the therapy itself.
THE FLUOROCORTINBUTLESS THE TREATMENT OF ALLERGIC RHINITIS
J Allergy Clin Immunol. 1991 Aug; 88 (2): 257-64.
Clinical trial testing the efficacy of Fluorocortinbutylester inhalation in the treatment of allergic rhinitis, showing a significant reduction in the number of mast cells and other cellular elements of inflammation.
Method of use and dosage
VASPIT ®
Cream for cutaneous use of 0.75 gr of Fluorcortinbutylester for 100 grams of product.
The precise dosage schedule required for VASPIT ® must necessarily be defined by the physician based on the patient's physiopathological conditions and the severity of his clinical picture.
In principle, the use of 2-3 applications a day is useful in the early stages of treatment to be subsequently reduced to a single daily application.
The use of the occlusive bandage should be prescribed by the doctor based on the patient's clinical condition.
Warnings VASPIT ® Fluorcortinbutilestere
Therapy with VASPIT ® must necessarily be preceded by a careful medical examination aimed at clarifying the nature of the lesions and the complained symptomatology, in order to implement an adequate therapeutic protocol.
The doctor should also inform the patient about the correct use of the product and the potential side effects related to the therapy itself, in order to optimize the therapeutic efficacy of the treatment and limit its potential side effects.
It would also be good to emphasize the importance of limiting topical corticosteroid therapy as soon as possible in order to reduce the incidence of potential side effects.
PREGNANCY AND BREASTFEEDING
The very low systemic absorption that the Fluorcortinbutylester encounters significantly reduces the potential contraindications to the use of the drug during pregnancy and lactation despite the use of corticosteroids in these phases of life is generally contraindicated.
Interactions
At the present time, known pharmacological interactions are not known, although it should be remembered that the simultaneous intake of cytochrome inhibitor drugs may increase blood concentrations of the amount of corticosteroid absorbed.
Contraindications VASPIT ® Fluorcortinbutilestere
The use of VASPIT ® is contraindicated in patients hypersensitive to the active substance or to one of its excipients, in patients with lesions associated with viral, bacterial and fungal infections not adequately treated.
Undesirable effects - Side effects
The use of VASPIT ® is generally well tolerated and has no clinically relevant side effects.
However, like all the other topical corticosteroids applied, also the Fluorcortinbutilestrere, especially when used for particularly long periods, could determine the appearance of local adverse reactions such as redness, burning, folliculitis, hypertrichosis, hypopigmentation and skin atrophy.
Note
VASPIT ® is a prescription-only drug.
